Fibrocell Science
-
Pharma Firm in New Jersey to Buy Exton-Based Biotechnology Company for $63.3 Million
Castle Creek Pharmaceuticals in New Jersey has reached an agreement to acquire Fibrocell Science, the Exton-based biotechnology company, for $63.3 million, writes John George for…
-
Exton’s Fibrocell Science Seeks Approval for Testing of Treatment for Rare Skin Disorder
Fibrocell Science in Exton is seeking approval from the FDA to start human testing of its experimental treatment for scleroderma, a rare autoimmune skin disorder,…
-
Chester County Briefly: December 12
Chester County Hero Fund James Vito, who recently retired as Chester County’s chief county detective after logging 37 years in the District Attorney’s Office, has…
-
Chester County Gene Therapy Firm Fibrocell Science Makes Pitch To Investors
With a trio of potential solutions for rare skin diseases being studied or soon to be studied on humans, an Exton research firm took the…
-
Exton Gene Therapy Developer Fibrocell Science Nears Second New Drug Application
After investing almost $3 million more cash in its operations, including $1 million more than the same quarter a year ago for gene therapy research…
-
Veteran Pharma CFO Stays In Chesco By Joining Fibrocell Team
The Wharton School alumnus and experienced chief financial officer Keith A. Goldan will stick around in Chester County in the wake of a major deal between…
-
Fibrocell Science Appoints New Interim Chief Financial Officer
Kimberly M. Smith is new interim chief financial officer, treasurer and corporate secretary at Fibrocell Science, Inc. David Pernock, Fibrocell’s chairman and CEO, thanked former…
-
Fibrocell Science Rings NASDAQ Bell, Investigates New Drug
Its been a busy week for the people at Fibrocell, the Exton based autologous cell therapy company focused on developing first-in-class treatments for rare and…
-
Fibrocell Science Plans R&D Day For Investors
Institutional investors and equity analysts are invited to a research and development day in New York on Sept. 24 sponsored by Fibrocell Science of Exton.…
-
Fibrocell Science, Inc. To Move Stock Listing To NASDAQ
In a move to attract investors, Fibrocell Science, Inc. of Exton is transferring its U.S. stock exchange listing from the New York Stock Exchange to…
-
Fibrocell, Focused On Research And Development, Announces Six-Month Financial Picture
Fibrocell Science, Inc. of Exton, an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases, spent…
-
Fibrocell Announces Exclusive License Agreement With UCLA
Fibrocell Science, Inc. of Exton now has an exclusive license agreement with the regents of the University of California at Los Angeles to commercially apply…
-
Fibrocell Share Price Jump Fueled By Insider Buys
What’s going on with Fibrocell Science’s (FCSC) shares? According to Zacks Investment Research, the online research company, shares of the Exton based cell therapy developer rose…
-
Fibrocell Of Exton Reports Strong Start For 2014
Exton based Fibrocell Science, Inc. recently reported its first quarter financials and what the company believes is a strong start for 2014. The company, in…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
